DOTS Technology
Harvard molecular biologist specializing in immunology, Dr. Gilboa-Geffen has extensive experience in Oligonucleotide therapeutic research. Her work has focused on therapeutic treatment of triple negative breast cancer, and she successfully led therapeutic constructs from IBD and Alzheimer’s disease. She has a PhD with Honors from the Hebrew University in Jerusalem, and did her post-doctoral training at Bonn University and Harvard Medical School.
This person is not in any offices
DOTS Technology
DOTS (Detection On the Spot) has a mission to make people’s lives better through a disruptive diagnostics platform that gives them information to make better decisions.